Vivos Therapeutics (VVOS) Other Non-Current Assets (2019 - 2026)
Vivos Therapeutics' (VVOS) quarterly Other Non-Current Assets came in at $254000.0 in Q1 2026, up 18.14% year-on-year from $215000.0 in Q1 2025, and up 11.4% on a QoQ basis from $228000.0 in Q4 2025.
Vivos Therapeutics (VVOS) Other Non-Current Assets (2019 - 2026) Analysis & Trends
Vivos Therapeutics (VVOS) has 8 years of Other Non-Current Assets data on file, last reported at $254000.0 in Q1 2026.
- On a quarterly basis, Other Non-Current Assets rose 18.14% year-over-year to $254000.0 in Q1 2026; TTM through Mar 2026 was $254000.0, a 18.14% increase from a year earlier, with the FY2025 full-year figure at $228000.0, up 5.56% from the prior year.
- Other Non-Current Assets for Q1 2026 stood at $254000.0, up from $228000.0 in the prior quarter.
- Over the last five years, Other Non-Current Assets for VVOS reached as high as $374000.0 in Q4 2022 and fell as low as $211000.0 in Q3 2025.
- Historically, Other Non-Current Assets has averaged $290705.9 across 5 years, with a median of $307000.0 in 2023.
- Across the five-year window, Other Non-Current Assets sank 30.19% in 2025 and gained 18.14% in 2026, its largest moves.
- Year by year, Other Non-Current Assets stood at $374000.0 in 2022, then declined by 17.91% to $307000.0 in 2023, then fell by 29.64% to $216000.0 in 2024, then advanced by 5.56% to $228000.0 in 2025, then increased by 11.4% to $254000.0 in 2026.
- Per Business Quant data, the three most recent Other Non-Current Assets figures were $254000.0 in Q1 2026, $228000.0 in Q4 2025, and $211000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | - |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 3.17 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 4.15 Bn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 2.05 Bn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 738.90 Mn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 285.90 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 828.89 Mn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 2.25 Bn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | 164.00 Mn |
| 10 | Vivos Therapeutics | 3.62 Mn | 1.38 Mn | 3.06 Mn | 254,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 254,000.00 |
| Dec 31, 2025 | 228,000.00 |
| Sep 30, 2025 | 211,000.00 |
| Jun 30, 2025 | 255,000.00 |
| Mar 31, 2025 | 215,000.00 |
| Dec 31, 2024 | 216,000.00 |
| Sep 30, 2024 | 276,000.00 |
| Jun 30, 2024 | 276,000.00 |
| Mar 31, 2024 | 308,000.00 |
| Dec 31, 2023 | 307,000.00 |
| Sep 30, 2023 | 307,000.00 |
| Jun 30, 2023 | 308,000.00 |
| Mar 31, 2023 | 308,000.00 |
| Dec 31, 2022 | 374,000.00 |
| Sep 30, 2022 | 372,000.00 |
| Jun 30, 2022 | 373,000.00 |
| Mar 31, 2022 | 354,000.00 |
| Dec 31, 2021 | 356,000.00 |
| Sep 30, 2021 | 355,698.00 |
| Jun 30, 2021 | 374,648.00 |